Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 343

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 343
---
 adding to the noted studies above. As such, WEED Israel worked with the Hebrew University in Jerusalem and with the top scientists
globally in the field of Cannabis & hemp. To that effect, WEED Israel looked to conduct clinical trials and product development that
would be the quality and acceptability of the FDA in the United States. Due to current laws and conditions in the USA, all research results
and product development for both Pharma & Non-Pharma products, cannot be introduced the United States marketplace. Since starting
in 2018, the USA has made vast improvements and advancements in the legalization of both Cannabis and hemp. As of the end of 2021 there
are 37 States that have approved a State level medical cannabis and hemp programs, along with the District of Colombia. In addition, there
are 17 States that have implemented or approved the “Adult Use” i.e. recreational psychoactive aspects of high THC usage of
cannabis.

In conjunction with WEED
Israel Cannabis Ltd., we made arrangements with Professor Elka Touitou to be available to be the head of WEEDs Israeli Advisory Board
to lead and assist us with clinical trials in cannabis & hemp research studies in Israel. Professor Touitou was the Head of the Innovative
Dermal, Transdermal and Transmucosal Delivery Lab at the Institute of Drug Research, The School of Pharmacy, HUJ, now retired but still
has HUJ clinical trial & independent studies/lab privileges. Professor Touitou is an internationally renowned authority in the field
of drug delivery and design of new technologies for efficient administration of drugs and development of new products. Professor Touitou
has been involved in Cannabinoid research since 1988 at The Hebrew University of Jerusalem, (HUJ) Jerusalem, Israel. Previously, WEED
was in the process of buying Professor Touitou’s various patents to include the bioavailability aspects of the cannabaceae plant.
However, after expending over $500,000 USD to acquire the Professor Touitou’s patents, we had to terminate the agreement in 2019
due to the downturn of the Cannabis marketplace, and specifically as to public cannabis companies, which could not be resumed due to the
Covid pandemic that was/is still ongoing globally. We have kept in constant contact with Professor Touitou thru our Managing Director
of WEED Israel, Mr. Elliot Kwestel. As of 2022, Dr. Touitou still has interest